1
|
Aykan N, Demir G, Disci R, Yalcin S, Turhal NS, Ozdogan M, Ozkan M, Yaren A, Camci C, Akbulut H. Profile of the colorectal (CRC) cancer (Ca) patients (PTS) in Turkey: A cross-sectional disease registry study—A Turkish Oncology Group trial. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.4_suppl.394] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
394 Background: CRC Ca is one of the most common Ca worldwide. This study was designed to determine the profile of recently diagnosed CRC Ca pts in Turkey. Methods: In this national, multicenter cross-sectional disease registry study, data for 968 pts diagnosed CRC Ca were analyzed. This non-interventional study was supported by sanofi-aventis. Results: From October 2008 to October 2009, 662 colon (68%), 306 rectum (32%) Ca pts were registered from 21 centers in 7 geographic regions of Turkey. Characteristics are as follows. Male 61%, mean age was 60±12 for colon and 57±13 for rectum Ca. The ratio of colon and rectum Ca were equal in the Black Sea region, colon Ca was higher in the other 5 regions except Eastern Anatolia where the highest percentage of rectum Ca was observed (55% vs 45%). Red meat consumption was significantly high only in Eastern Anatolia (p<0.001). The consumption of alcohol, fruit and vegetables didn't show any difference. The percentage of smoking was slightly higher in the rectum Ca group (21% vs 16%, NS). The CRC family history was a risk factor in 7.4% colon, and in 5.6% rectum Ca pts. Among all pts, 1.5% had familial poliposis and only 0.4% had Lynch syndrome. Hypertension (29%) and diabetes mellitus (15%) were the most frequent concomitant diseases. Mean body mass index was 26 ± 4 in colon and 26 ± 5 in rectum Ca pts. Median time between the onset of symptoms and diagnosis was 3 months (mo) for colon and 4 mo for rectum Ca pts. For 46% of pts this time was longer than 4 mo. The mean weight loss in last 6 mo was slightly higher in colon Ca pts (3.9 vs 3.4 kg). Anemia was more frequent in colon Ca pts (p<0.05). Primary tumor location: sigmoid 37% for colon Ca, distal rectum 61% for rectum Ca. In total, 86% of pts were operated (88% of colon, 80% of rectum Ca). In 26% of pts emergency surgery was performed. AJCC staging at diagnosis: I-7%, II-26%, III-35%, IV-32% in colon and I-14%, II-22%, III-39%, IV:25% in rectum. Conclusions: This study showed that colon Ca was more frequent and most of the cases were operated. Data also revealed that pts were diagnosed at considerably later stages. The role of the consumption of red meat, obesity and smoking should be evaluated in larger trial in the future. [Table: see text]
Collapse
Affiliation(s)
- N. Aykan
- University of Istanbul, Istanbul, Turkey; Medical Oncology Department, Istanbul Bilim University School of Medicine, Istanbul, Turkey; Istanbul University Institute of Oncology, Istanbul, Turkey; Hacettepe University, Ankara, Turkey; Medical Oncology Department, Marmara University Hospital, Istanbul, Turkey; Department of Medical Oncology, Akdeniz University, Antalya, Turkey; Department of Medical Oncology, Erciyes University Medical Faculty, Kayseri, Turkey; Pamukkale University Denizli, Istanbul,
| | - G. Demir
- University of Istanbul, Istanbul, Turkey; Medical Oncology Department, Istanbul Bilim University School of Medicine, Istanbul, Turkey; Istanbul University Institute of Oncology, Istanbul, Turkey; Hacettepe University, Ankara, Turkey; Medical Oncology Department, Marmara University Hospital, Istanbul, Turkey; Department of Medical Oncology, Akdeniz University, Antalya, Turkey; Department of Medical Oncology, Erciyes University Medical Faculty, Kayseri, Turkey; Pamukkale University Denizli, Istanbul,
| | - R. Disci
- University of Istanbul, Istanbul, Turkey; Medical Oncology Department, Istanbul Bilim University School of Medicine, Istanbul, Turkey; Istanbul University Institute of Oncology, Istanbul, Turkey; Hacettepe University, Ankara, Turkey; Medical Oncology Department, Marmara University Hospital, Istanbul, Turkey; Department of Medical Oncology, Akdeniz University, Antalya, Turkey; Department of Medical Oncology, Erciyes University Medical Faculty, Kayseri, Turkey; Pamukkale University Denizli, Istanbul,
| | - S. Yalcin
- University of Istanbul, Istanbul, Turkey; Medical Oncology Department, Istanbul Bilim University School of Medicine, Istanbul, Turkey; Istanbul University Institute of Oncology, Istanbul, Turkey; Hacettepe University, Ankara, Turkey; Medical Oncology Department, Marmara University Hospital, Istanbul, Turkey; Department of Medical Oncology, Akdeniz University, Antalya, Turkey; Department of Medical Oncology, Erciyes University Medical Faculty, Kayseri, Turkey; Pamukkale University Denizli, Istanbul,
| | - N. S. Turhal
- University of Istanbul, Istanbul, Turkey; Medical Oncology Department, Istanbul Bilim University School of Medicine, Istanbul, Turkey; Istanbul University Institute of Oncology, Istanbul, Turkey; Hacettepe University, Ankara, Turkey; Medical Oncology Department, Marmara University Hospital, Istanbul, Turkey; Department of Medical Oncology, Akdeniz University, Antalya, Turkey; Department of Medical Oncology, Erciyes University Medical Faculty, Kayseri, Turkey; Pamukkale University Denizli, Istanbul,
| | - M. Ozdogan
- University of Istanbul, Istanbul, Turkey; Medical Oncology Department, Istanbul Bilim University School of Medicine, Istanbul, Turkey; Istanbul University Institute of Oncology, Istanbul, Turkey; Hacettepe University, Ankara, Turkey; Medical Oncology Department, Marmara University Hospital, Istanbul, Turkey; Department of Medical Oncology, Akdeniz University, Antalya, Turkey; Department of Medical Oncology, Erciyes University Medical Faculty, Kayseri, Turkey; Pamukkale University Denizli, Istanbul,
| | - M. Ozkan
- University of Istanbul, Istanbul, Turkey; Medical Oncology Department, Istanbul Bilim University School of Medicine, Istanbul, Turkey; Istanbul University Institute of Oncology, Istanbul, Turkey; Hacettepe University, Ankara, Turkey; Medical Oncology Department, Marmara University Hospital, Istanbul, Turkey; Department of Medical Oncology, Akdeniz University, Antalya, Turkey; Department of Medical Oncology, Erciyes University Medical Faculty, Kayseri, Turkey; Pamukkale University Denizli, Istanbul,
| | - A. Yaren
- University of Istanbul, Istanbul, Turkey; Medical Oncology Department, Istanbul Bilim University School of Medicine, Istanbul, Turkey; Istanbul University Institute of Oncology, Istanbul, Turkey; Hacettepe University, Ankara, Turkey; Medical Oncology Department, Marmara University Hospital, Istanbul, Turkey; Department of Medical Oncology, Akdeniz University, Antalya, Turkey; Department of Medical Oncology, Erciyes University Medical Faculty, Kayseri, Turkey; Pamukkale University Denizli, Istanbul,
| | - C. Camci
- University of Istanbul, Istanbul, Turkey; Medical Oncology Department, Istanbul Bilim University School of Medicine, Istanbul, Turkey; Istanbul University Institute of Oncology, Istanbul, Turkey; Hacettepe University, Ankara, Turkey; Medical Oncology Department, Marmara University Hospital, Istanbul, Turkey; Department of Medical Oncology, Akdeniz University, Antalya, Turkey; Department of Medical Oncology, Erciyes University Medical Faculty, Kayseri, Turkey; Pamukkale University Denizli, Istanbul,
| | - H. Akbulut
- University of Istanbul, Istanbul, Turkey; Medical Oncology Department, Istanbul Bilim University School of Medicine, Istanbul, Turkey; Istanbul University Institute of Oncology, Istanbul, Turkey; Hacettepe University, Ankara, Turkey; Medical Oncology Department, Marmara University Hospital, Istanbul, Turkey; Department of Medical Oncology, Akdeniz University, Antalya, Turkey; Department of Medical Oncology, Erciyes University Medical Faculty, Kayseri, Turkey; Pamukkale University Denizli, Istanbul,
| | | |
Collapse
|